Clinical outcomes of transcatheter edge-to-edge repair in patients with acute mitral regurgitation complicated by cardiogenic shock: a systematic review and meta-analysis.

BACKGROUND

Acute mitral regurgitation (AMR) complicated by cardiogenic shock (CS) is a critical cardiovascular emergency associated with high morbidity and mortality. Surgical intervention is often not feasible due to the unstable clinical status of these patients. Transcatheter edge-to-edge repair (TEER) has emerged as a minimally invasive alternative, yet its safety and efficacy in this specific population remain uncertain. This study aimed to systematically evaluate and synthesize the evidence on the clinical outcomes of TEER in patients with AMR complicated by CS.

METHODS

Databases including PubMed, Embase, and Web of Science were searched through March 4, 2025. Eligible studies included adult patients with AMR and CS undergoing TEER and reporting clinical outcomes. Data were synthesized using a random-effects model.

RESULTS

The pooled in-hospital mortality rate following TEER was 17.8% (95% CI: 11.2-25.2%). One-month mortality was 7.9% (95% CI: 1.1-16.8%), six-month mortality was 21.0% (95% CI: 11.2-32.7%), and one-year mortality was 36.5% (95% CI: 34.9-38.2%). Among patients with degenerative MR, the one-year mortality was 7.9% (95% CI: 0.8-19.0%), while for functional MR it was 9.4% (95% CI: 1.3-21.5%). Postprocedural MR reduction to ≤ grade 2 was achieved in 86.2% of patients (95% CI: 70.7-97.3%). The intra-aortic balloon pump (IABP) application rate was 57.9% (95% CI: 24.2%-88.5%). Compared to usual care, TEER significantly reduced in-hospital mortality (OR = 0.64; 95% CI: 0.51-0.81; P < 0.01). However, no significant reduction was found in rehospitalization risk (OR = 0.65; 95% CI: 0.14-3.03; P = 0.59).

CONCLUSION

TEER appears to be a promising therapeutic option for patients with AMR complicated by CS. Compared to usual care, it is associated with significantly lower in-hospital mortality. However, high heterogeneity and low certainty of evidence highlight the need for further high-quality prospective studies to validate long-term outcomes and optimize patient selection.

CLINICAL TRIAL NUMBER: Not applicable.